SEC filings and other documents

Product innovation, robotics, and strong execution drive growth and margin expansion.

Innovative implants, AI planning, and outpatient focus drive rapid growth and market leadership.

Q2 revenue up 56% YoY, guidance raised, and strong product innovation drives growth.

Director elections and auditor ratification approved; no stockholder questions submitted.

Innovative implants and AI-driven planning fuel rapid growth in the $2.8B shoulder arthroplasty market.

Q1 revenue surged 65% year-over-year, prompting a raised full-year outlook and margin gains.

Innovative implants and AI-driven planning fuel rapid growth and high margins in shoulder arthroplasty.

AI-driven innovation and outpatient focus fuel strong growth and new opportunities in shoulder arthroplasty.

Q4 revenue up 65% year-over-year; 2026 guidance targets 31–37% growth with strong margins.

Disruptive InSet Glenoid and AI-driven platform fuel rapid growth in shoulder arthroplasty.

Portable robotics and surgeon-focused innovation fuel rapid growth and strong margins.

AI-driven planning and streamlined implants drive growth as ASC adoption accelerates.

Revenue up 58% and guidance raised, but net loss widened on higher expenses.

Innovative implants and AI-driven planning fuel rapid growth in the shoulder arthroplasty market.

Strong Q2 growth and innovative, efficient solutions drive momentum in the shoulder arthroplasty market.

Q2 2025 revenue up 33% to $11M; net loss $19.2M; 2025 revenue outlook $42–44M.

Innovative solutions and strong growth are redefining the global shoulder arthroplasty market.